Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Collect patient data and to monitor the clinical use (safety and efficacy) of the device
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proper closure of the PVL (defined as Reduction in paravalvular regurgitation of ≥ one grade as assessed by echocardiography pre vs post implantation) and/or reduction in the number of hemolysis related transfusions. | 6 month following implantation | |
| Absence of device -and/or procedure-related Serious Adverse Events (SAEs) including deaths, stroke (ischemic stroke that occurs within 24 hours following implantation), systemic embolism or device embolizations. | 6 month following implantation |
Not provided
Not provided
Inclusion criteria:
- Patients with PVL associated hemolysis, recurrent blood transfusions, or hemodynamically significant heart failure
Exclusion criteria
The device is contraindicated for patients known to have any of the following:
Not provided
Not provided
Not provided
Patients with aortic or mitral PVL
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardiovascular Department | Bergamo | 24125 | Italy |
Not provided
Not provided
Not provided
Not provided